Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | KLK7 | P49862 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24118611 | 1.00 | CA1 (0.44) | CA1CA2KLK7MEN1KMT2A | |
| SCHEMBL23592440 | 1.00 | CA1 (0.44) | CA1CA2KLK7MEN1KMT2A | |
| SCHEMBL26783043 | 0.88 | CA1 (0.44) | CA1CA2KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL24118081 | 0.86 | MAPT (0.51) | KLK7MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL24118254 | 0.83 | FPR2 (0.48) | MEN1KMT2AMAPTCYP1A2CYP2C9 | |
| SCHEMBL24118197 | 0.82 | IDO1 (0.55) | KLK7MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL24118347 | 0.81 | LMNA (0.50) | KLK7MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL24118272 | 0.78 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL23593322 | 0.77 | POLB (0.48) | KLK7MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL25069089 | 0.75 | CTSS (0.52) | CA2KLK7MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352320-B2 | Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210393600-A1 | Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210198190-A1 | NOVEL SUBSTITUTED [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198190-A1 | NOVEL SUBSTITUTED [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | IDO1, IDO2, TPH1 | CA1 1540/4885CA2 2336/4885KLK7 4437/4885 |
| US-20210393600-A1 | Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors | IDO1, IDO2, TPH1 | CA1 1496/4885CA2 2151/4885KLK7 4369/4885 |
| US-11352320-B2 | Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, TPH1 | CA1 1441/4885CA2 2210/4885KLK7 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.